Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 257 citations, 2019 year and hybrid oa status.